Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | MicrobiomeTrials← Back to trialsNCT05907759
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-07-10Est. Completion: 2034-08-01
Enrollment target: 28 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
HIVKaposi's SarcomaLymphomasMulticentric Castleman's DiseasePrimary Effusion Lymphoma
BACKGROUND:
* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or …
Bethesda, United States
KSHV Inflammatory Cytokine Syndrome (KICS)KSHVHHV-8
Background:
\- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associ…
Bethesda, United StatesEst. completion Dec 31, 2028
AIDS-Related Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedLugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8Plasmablastic LymphomaPrimary Effusion Lymphoma
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (ri…
Multiple LocationsEst. completion Apr 30, 2028